Although the RGZinhibitory effect on cell proliferation and viability has already been reportedin H295R cells [10, 16], this is the first time that RGZ IC50 andmaximal effect have been calculated with an appropriate statistical analysis [17],thus validating the current dose of 20 μM used in cancer studies and suggestingthat the anti-proliferative effects of RGZ are obtained at higherconcentrations than the ones effective on insulin sensitivity [13]. Here, INS is linked to cancer.